|Videos|August 18, 2016

How Can We Improve Antimicrobial Stewardship in Solid Organ Transplant Patients?

Monica Mahoney, PharmD, BCPS-AQ ID, clinical pharmacy coordinator of infectious diseases at Beth Israel Deaconess Medical Center, discusses how collaboration with transplant counterparts is needed to provide optimal treatment.

Monica Mahoney, PharmD, BCPS-AQ ID, clinical pharmacy coordinator of infectious diseases at Beth Israel Deaconess Medical Center, discusses how collaboration with transplant counterparts is needed to provide optimal treatment.

Interview Transcript (slightly modified for readability)

“Increased collaboration with our transplant counterparts, [is needed] so that we [as infectious disease pharmacists] can gather more data and have more information on the optimal treatment of these patients, be it duration of therapy, what we should be using for impaired therapy, combination therapy, and how these therapies impact the immunosuppression of the patients in terms of drug [to] drug interactions.”


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.